IEQ Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$640K Sell
76,838
-150,583
-66% -$1.42M ﹤0.01% 1247
2026
Q2
$2.27M Buy
+227,421
New +$2.06M 0.01% 760
2025
Q4
– Sell
-71,950
Closed -$546K – 1867
2025
Q3
$546K Sell
71,950
-52,433
-42% -$437K ﹤0.01% 1251
2025
Q2
$1.11M Buy
124,383
+1,680
+1% +$15.6K 0.01% 822
2025
Q1
$920K Buy
122,703
+93,267
+317% +$752K 0.01% 783
2024
Q4
$221K Buy
+29,436
New +$223K ﹤0.01% 1162

Other funds holding BCRX

IEQ Capital's BCRX Position: Q3 2026 in Review

IEQ Capital reduced its BioCryst Pharmaceuticals (BCRX) stake by 66% in Q3 2026, selling an estimated $1.42M and leaving 76,838 shares worth $640K. The position accounts for ﹤0.01% of the portfolio, ranked #1247.

IEQ Capital first reported a position in BCRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.27M in Q2 2026. 333 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

  • IEQ Capital held 76,838 shares of BioCryst Pharmaceuticals worth $640K as of Q3 2026.
  • IEQ Capital sold 150,583 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $1.42M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of IEQ Capital's portfolio in Q3 2026, its #1247 holding.
  • IEQ Capital first reported a position in BioCryst Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • IEQ Capital's BioCryst Pharmaceuticals position peaked at $2.27M in Q2 2026.
  • 333 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on IEQ Capital's 13F filing for Q3 2026, filed 10 Nov 2026.